Overview

Phase 1 Study of Quizartinib

Status:
Completed

Trial end date:
2018-11-13

Target enrollment:

Participant gender:

Summary

This is a dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of quizartinib for Japanese acute myeloid leukemia (AML) subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Daiichi Sankyo Co., Ltd.